News
ACOG
5.44
-3.37%
-0.19
Weekly Report: what happened at ACOG last week (0303-0307)?
Weekly Report · 4d ago
Adobe, DICK's Sporting Goods, Dollar General To Report Results As Investors Look To Inflation Report
Seeking Alpha · 6d ago
Weekly Report: what happened at ACOG last week (0224-0228)?
Weekly Report · 03/03 10:48
Weekly Report: what happened at ACOG last week (0217-0221)?
Weekly Report · 02/24 10:48
Weekly Report: what happened at ACOG last week (0210-0214)?
Weekly Report · 02/17 10:46
Alpha Cognition secures additional patent for Zunveyl from USPTO
TipRanks · 02/12 13:42
ALPHA COGNITION SECURES ADDITIONAL U.S. PATENT FOR ZUNVEYL (BENZGALANTAMINE) IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER’S DISEASE
Reuters · 02/12 13:30
Weekly Report: what happened at ACOG last week (0203-0207)?
Weekly Report · 02/10 10:41
Weekly Report: what happened at ACOG last week (0127-0131)?
Weekly Report · 02/03 10:45
Weekly Report: what happened at ACOG last week (0120-0124)?
Weekly Report · 01/27 10:47
Weekly Report: what happened at ACOG last week (0113-0117)?
Weekly Report · 01/20 10:41
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
TipRanks · 01/14 13:50
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
Barchart · 01/14 07:30
Weekly Report: what happened at ACOG last week (0106-0110)?
Weekly Report · 01/13 10:41
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
TipRanks · 01/08 14:00
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Benzinga · 01/08 13:43
Alpha Cognition announces $44M licensing agreement for commercialization of ZUNVEYL in China
Seeking Alpha · 01/08 13:41
ALPHA COGNITION ANNOUNCES A $44 MILLION EXCLUSIVE LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ZUNVEYL (BENZGALANTAMINE), AN FDA-APPROVED TREATMENT FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE, IN CHINA
Reuters · 01/08 13:30
ALPHA COGNITION INC: REMAINS ON TRACK TO LAUNCH ZUNVEYL IN UNITED STATES IN Q1 2025
Reuters · 01/08 13:30
Weekly Report: what happened at ACOG last week (1230-0103)?
Weekly Report · 01/06 10:47
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
More
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.